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ALDH
bright cells in human tumor cells lines, xenografts and lesions have been shown to have characteristics of cancer
stem cells (CSC). We have shown that these cells are recognized by ALDH1A1-specific CD8
+ T cells in vitro and in vivo. The
results support the potential of ALDH1A1-based immunotherapy to target CSC.
Cancer Stem Cells and ALDH1A1
Not without controversy, cancer stem cells
(CSC) are considered capable of symmet-
rical or asymmetric self-renewal, resistance
to standard chemo- or radio- therapies, less
differentiated, and tumorgenic, the latter
evident by ability in low numbers to
establish tumors in immunodeficient
mice.
1,2 As the failure of current therapies
to control cancer can be attributed to their
inability to eliminate CSC, there is a
critical need to develop strategies that
eliminate these “stem cell-like” tumor
cells.
Employing the methods of flow cyto-
metry-based studies of hematopoietic and
leukemic stem cells, highly enriched popu-
lations of tumor cells with “stem cell-like”
properties have been isolated from many
types of human carcinomas. Most recently,
it is based on elevated expression of
aldehyde dehydrogenase (ALDH) activity.
Incombination withDEAB,aninhibitorof
the ALDH1A1, -A2, -A3 and ALDH3A1
isoforms, the flow reagent ALDEFLUOR
identifies ALDH
+ cells.
3 Expression of
ALDH1A1, which metabolizes genotoxic
aldehydes, is critical to the chemoradio-
resistance of normal stem cells and tumor
cells. However, while it is not absolute that
all CSC are ALDH
+ cells, isolated popula-
tions of ALDH
+ tumor cells certainly have
characteristics distinct from the remaining
tumor cell population.
Identification of ALDH1A1 as a
Shared Tumor Antigen (TA)
In a collaborative study with Dr. Theresa
Whiteside, my laboratory identified
ALDH1A188–96 peptide as a shared CTL-
defined human tumor antigen (TA) in
squamous cell carcinoma of the head and
neck (SCCHN).
4 Given that only one or
two exchanges distinguish the peptides
encoded by codons 88–96 of the ALDH1/
3 isoforms, particular attention was paid to
ensure that the HLA-A2-restricted CTL
were specific for the ALDH1A188–96 pep-
tide. Furthermore, ALDH1A1 expression at
the protein level correlated with the severity
of oral mucosal dysplasia and less differ-
entiated and more aggressive SCCHN
lesions. These findings suggested that it
might be an early marker for development
of SCCHN and an attractive target for
immunoprevention aswell as therapy of this
disease.
Somewhat unappreciated at first, as one
became more aware of the roles of
ALDH1A1 in retinoic acid metabolism
and detoxification of genotoxic aldehydes,
its identification as a TA gained our
attention. In line with the work of
Mackenzie and colleagues dealing with
SCCHN CSC,
5 ALDH1A1
+ cells isolated
from several of our SCCHN cell lines used
in our studies were CD44
+, tended to have
a primitive morphology and clonogenic,
whereas ALDH1A1
negcells were not.These
findings combined with the seminal iden-
tification of ALDH
+ breast cancer cells as
CSC
6 prompted focusing our attention on
targeting CSC in human cancers with
ALDH1A1-specific CTL.
7
Targeting ALDH
bright Cells
with ALDH1A1-Specific CTL
In ensure the purity of the ALDH
+ cells
being analyzed in our studies, ALDH
bright
cells, which have a mean fluorescence
intensity (MFI) twice that of the bulk
ALDH
+ cell population in a sample, were
isolated. Re-analysis showed that sorted
ALDH
bright cells were ~95% ALDH
+,
whereas sorted “bulk” ALDH
+ cells con-
sisted of only 65% ALDH
+ cells.
Critically, the ALDH
bright cells sorted from
HLA-A2
+ breast MDA-MB-231, SCCHN
PCI-13 and pancreas MIA PaCa-2 cell
lines were tumorigenic. Furthermore,
qRT/PCR analysis of sorted ALDH
bright
cells from these cell lines indicated the
dominant expression of ALDH1A1
mRNA relative to other ALDH1/3 iso-
form mRNA.
Most importantly, whereas recognition
of SCCHN cell lines by ALDH1A1-
specific CTL in ELISPOT IFNc assays
requires pretreatment with IFNc (to
upregulate antigen processing and presenta-
tion), recognition of sorted ALDH
bright cells
does not. One presumes this is due to
elevated ALDH1A1 expression in these
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peptide complexes for CTL recognition
and detection in this assay. The research
subsequently was facilitated by (1) using
artificial antigen presenting cells to induce
ALDH1A1-specific CTL from normal
donor and patient-derived lymphocytes
8;
T-cell effector yields were 10 to 30
that obtained previously, and (2) direct
detection of the elimination by
ALDH1A1-specific CTL of ALDH
+/
ALDH
bright cells in cell lines and dis-
aggregated xenografts and surgically
removed patient lesions samples in a
flow-based ALDEFLUOR assay (Fig.1).
Figure1. ALDH
bright CSC but not normal ALDH
+/low cells are recognized by HLA-A2 restricted, ALDH1A1-specific CTL. (A) Unlike bulk population of tumor
cells, ALDH
bright CSC are resistant to chemoradiation therapy but sensitive to ALDH1A1-specific CTL resulting in control of tumor growth. (B) Relative to
levels of ALDH1A1 expressed by ALDH
bright CSC, normal CD34
+ HSC are ALDH
+/low and not recognized by ALDH1A1-specific CTL.
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show the efficacy of ALDH1A1-specific
CTL-based therapy performed in collabora-
tion with Dr. Hui Wang’ laboratory,
particularly important was adoptive transfer
of CTL to mice following surgical removal
of primary MDA-MB-231-derived ortho-
topic xenografts. These mice generally
succumb to metastases within two months.
Following their surgery, however, treatment
of mice with ALDH1A1-specific CTL until
all untreated control mice died increased
their survival past seven months.
Given that CD34
+ hematopoietic stem
cells (HSC) express ALDH1A1,
3 starting
from our initial study, it has been critical
to show that HSC are not recognized by
ALDH1A1-specific CTL. To date, there is
no indication that HSC, even pretreated
with IFNc, are recognized in vitro by
ALDH1A1-specific CTL; most likely,
because the ALDH1A1 level is lower than
in tumor cells. In ancillary mouse experi-
ments, immunization of mice with dend-
ritic cells transfected with aldh1a1 cDNA
(mouse ALDH1A1 homolog) induced
aldh1a1-reactive T cells and had no overall
effect on hematopoiesis using absolute
numbers and CD4
+/CD8
+ T cell ratios as
surrogate markers.
Future Directions
Future research efforts require the use of
primary tumors arising in genetically modi-
fied mouse models of human cancer to
demonstrate efficacy of ALDH1A1-based-
active and passive immunotherapy in
eliminating CSC and controlling tumor
growth and metastases. However, any type
of therapy promotes tumor escape. To
minimize this, we are investigating the
efficacy of combinatorial strategies to target
CSC by combining ALDH1A1-specific
CTL with stem cell-signaling pathway
inhibitors
9 and antibody-based therapies.
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